StocksMedium•9 November 2026•
1 min read
AMG Hits Record $974B AUM as Compugen Eyes 2027 Clinical Results
Key Facts
1AMG reported diluted EPS of $6.64 with assets under management reaching a record $974 billion.
2Compugen expects Phase 3 rilvegostomig results from partner AstraZeneca in the second half of 2027.
3Hain Celestial reported financial results for its fiscal first quarter ended September 30, 2026.
AMG reported diluted earnings per share of $6.64 for the third quarter of 2026, with assets under management reaching a record $974 billion. GlobeNewswire reported that the company achieved net client cash flows of approximately $21 billion during the quarter, driven by continued strength in alternative strategies.
Compugen announced that it expects Phase 3 clinical trial results for rilvegostomig from its partner AstraZeneca in the second half of 2027. According to a company statement, CGEN stock closed at $1.96 on November 6, 2026, while AZN closed at $186.43 on the same date. Separately, Hain Celestial reported financial results for the quarter ended September 30, 2026, with HAIN stock closing at $0.1494 on November 6, 2026.